NL-OMON49006招募中2 期
A Phase IIb, 2-Arm, Randomized, Double-blind, Placebo-Controlled, Multicentre Study to Optimize Diamyd® Therapy Administered into Lymph Nodes Combined with Oral Vitamin D to Investigate the Impact on the Progression of Type 1 diabetes - DIAGNODE-2
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 2
研究概览
简要总结
Trial is onging in other countries
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 至 99（—）
入选标准
- •1. Informed consent given by patients and/or patient*s parent(s) or legal
- •acceptable representative(s) (guardian(s)) according to national regulations
- •2. T1D according to the ADA classification diagnosed <=6 months at the time of
- •3. Age: >=12 and <25 years old
- •4. Fasting C-peptide >=0.12 nmol/L
- •5. Positive for GAD65A but < 50 000 IU/ml
- •6. Females must agree to avoid pregnancy and have a negative urine pregnancy
- •Patients of childbearing potential must agree to use adequate contraception,
- •until one (1) year after the last administration of Diamyd. Adequate
- •contraception is as follows:
- •For females of childbearing potential:
- •a. oral (except low*dose gestagen (lynestrenol and norestisteron)), injectable,
- •or implanted hormonal contraceptives
- •b. combined (estrogen and progestogen containing)
- •c. oral, intravaginal or transdermal progesterone hormonal contraception
- •associated with inhibition of ovulation
- •d. intrauterine device
- •e. intrauterine hormone-releasing system (for example, progestin*releasing coil)
- •f. bilateral tubal occlusion
- •g. vasectomized male (with appropriate post vasectomy documentation of the
- •absence of sperm in the ejaculate)
- •h. male partner using condom
- •i. abstinence from heterosexual intercourse , For males of childbearing
- •a. condom (male)
- •b. abstinence from heterosexual intercourse
排除标准
- •1. Previous or current treatment with immunosuppressant therapy (although
- •topical or inhaled steroids are accepted)
- •2. Continuous treatment with anti-inflammatory drug (sporadic treatment e.g.
- •because of headache or in connection with fever a few days will be accepted)
- •3. Treatment with any oral or injected anti-diabetic medications other than
- •4. Treatment with Vitamin D, marketed or not, or unwilling to abstain from such
- •medication during the trial
- •5. A history of anemia or significantly abnormal hematology results at screening
- •6. A history of epilepsy, head trauma or cerebrovascular accident, or clinical
- •features of continuous motor unit activity in proximal muscles
- •7. Clinically significant history of acute reaction to vaccines or other drugs
- •in the past
- •8. Treatment with any vaccine, including influenza vaccine, within 4 months
- •prior to planned first study drug dose or planned treatment with any vaccine up
- •to 4 months after the last injection with study drug.
- •9. Participation in other clinical trials with a new chemical entity within the
- •previous 3 months
- •10. Inability or unwillingness to comply with the provisions of this protocol
- •11. A history of alcohol or drug abuse
- •12. A significant illness other than diabetes within 2 weeks prior to first
- •13. Known HIV or hepatitis
- •14. Females who are lactating or pregnant (the possibility of pregnancy must be
- •excluded by urine βHCG on-site within 24 hours prior to the Diamyd/placebo
- •15. Presence of associated serious disease or condition, including active skin
- •infections that preclude intralymphatic injection, which in the opinion of the
- •investigator makes the patient non-eligible for the study
- •16. Deemed by the investigator not being able to follow instructions and/or
- •follow the study protocol
研究者
相似试验
已完成
2 期
A Phase 2b Multicentre, Randomised, Double-Blind, Active Controlled, Parallel Group Dose-Ranging Study to Assess the Efficacy, Safety and Tolerability of Zibotentan and Dapagliflozin in Patients with Chronic Kidney Disease with Estimated Glomerular Filtration Rate (eGFR) Between 20 and 60 mL/min/1.73 m2Chronic Kidney DiseaseNL-OMON52170Astra Zeneca9
已完成
2 期
A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS)Motor Neuron DiseaseAmyotrophic Lateral Sclerosism (ALS)10029317NL-OMON45879Cytokinetics, Inc.11
已完成
2 期
A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 in Patients With Heterozygous Familial HypercholesterolemiaHeterozygous Familial HypercholesterolemiaNL-OMON45499Madrigal Pharmaceuticals, Inc.24
已完成
2 期
A Phase 2, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Study of LY3074828 in Subjects with Moderate to Severe Ulcerative Colitisinflamatory bowel disease10017969Ulcerative colitisNL-OMON46940Eli Lilly and Company7
已完成
2 期
A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)Duchenne Muscular DystrophyNL-OMON50318ReveraGen BioPharma, Inc.7